Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1705 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg \[Hyzaar(R)\]) treatment for a period of at least three months on serum uric acid levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Losartan or Eprosartan on Fructose Hyperuricemia

NCT04954560

Uric Acid Concentration, Serum, Quantitative Trait Locus 7

COMPLETED NA

Gout Dose Response Study

NCT00955981

Hyperuricemia

COMPLETED PHASE2

Effect of Febuxostat on Blood Pressure

NCT01496469

Hypertension

COMPLETED PHASE2

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

NCT05347498

Primary Gout With Hyperuricemia in Adults

UNKNOWN PHASE1

Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189

NCT01361646

Hyperuricemia Gout

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Participants

Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant was \>20 years and \<75 years of age on the index date (i.e., the date of initiating MK-0954A therapy)
* Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months
* Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg
* Had the following records documented in the chart during the data collection period:

* medical history and co-morbidities (if available)
* sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg
* serum electrolytes, serum creatinine, and pre-meal sugar (if available)
* prescription information of all antihypertensive regimens

Exclusion Criteria

* Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg
* Serum creatinine \>2 mg/dL

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No